

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2022

**NextCure, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-38905**  
(Commission File Number)

**47-5231247**  
(IRS Employer Identification No.)

**9000 Virginia Manor Road, Suite 200**  
**Beltsville, Maryland**  
(Address of principal  
executive offices)

**20705**  
(Zip Code)

Registrant's telephone number, including area code: **(240) 399-4900**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On May 5, 2022, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press release issued by NextCure, Inc. dated May 5, 2022</a>
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 5, 2022

**NEXTCURE, INC.**

By: /s/ Steven P. Cobourn

Name: Steven P. Cobourn

Title: Chief Financial Officer

---

**NextCure Provides Business Update and Reports First Quarter 2022 Financial Results**

- *On track to report data from all three clinical programs in the second half of 2022*
- *First quarter ending cash of \$201.3 million expected to fund operations into the first quarter of 2024*

**BELTSVILLE, Md. – May 5, 2022** -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2022 financial results and provided a business update.

“In the first quarter, we continued to advance our pipeline of four product candidates towards key clinical milestones,” said Michael Richman, NextCure’s President and Chief Executive Officer. “In the second half of 2022, we anticipate clinical trial updates for NC318, NC410, and NC762, as well as an IND filing for NC525. We also expect our quarter-end cash position of \$201.3 million will fund our operations into the first quarter of 2024.”

**Expected Milestones**

We believe we are on track to meet the following milestones during the second half of 2022:

- NC318 Phase 2 update: fourth quarter of 2022 (Amended Phase 2 with patient selection and increased dosing).
- NC318 anti-PD-1 combo initial data second half of 2022 (Yale University Investigator-Initiated trial).
- NC410 Phase 1 update: second half of 2022.
- NC762 Phase 1 initial data: second half of 2022.
- NC525 Investigational New Drug Application (IND) filing: fourth quarter of 2022.

**Financial Guidance**

Based on its current research and development plans, NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into the first quarter of 2024.

---

## Financial Results for First Quarter March 31, 2022

- Cash, cash equivalents, and marketable securities, excluding restricted cash, as of March 31, 2022, were \$201.3 million as compared with \$219.6 million as of December 31, 2021. The decrease of \$18.3 million primarily reflects cash used to fund operations.
- Research and development expenses were \$15.0 million for the quarter ended March 31, 2022 as compared to \$12.4 million for the quarter ended March 31, 2021. The increase of \$2.6 million was driven primarily by additional clinical and lab-related costs.
- General and administrative expenses were \$5.8 million for the quarter ended March 31, 2022 as compared with \$4.9 million for the quarter ended March 31, 2021. The increase of \$0.9 million was primarily related to additional personnel-related costs.
- Net loss was \$20.6 million for the quarter ended March 31, 2022 as compared with \$16.5 million for the quarter ended March 31, 2021. The changes in net loss from the previous year's quarter were primarily due to increased research and development expenses.

## About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. <http://www.nextcure.com>

---

## Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "may," "will," "potential," "expects," "believes," "anticipates," "intends," "hope," "towards," "forward," "later" and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the development plans for our immunomedicines, statements about the progress and evaluation and expected timing of results of NextCure's ongoing clinical trial of NC318, expectations regarding the potential benefits, activity, effectiveness and safety of NC318, expectations regarding the investigator initiated trial conducted by Yale, the expected timing of results of NextCure's ongoing clinical trial of NC410, the development plans for NC762, the plans for the Investigative New Drug (IND) Application filing for NC525, NextCure's financial guidance, expected upcoming milestones, and NextCure's plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure's business, including NextCure's clinical trials, third parties on which NextCure relies and NextCure's operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and no products approved for commercial sale; NextCure's history of significant losses; NextCure's need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure's FIND-IO™ platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including in Item 1A of NextCure's most recent Form 10-K and elsewhere in the Company's filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, except as required by law, even if expectations change.

### Investor Inquiries

Timothy Mayer, Ph.D.  
NextCure, Inc.  
Chief Operating Officer  
(240) 762-6486  
[IR@nextcure.com](mailto:IR@nextcure.com)

## Selected Financial Information

### Selected Statement of Operations Items:

	Three Months Ended	
	March 31,	
	2022	2021
<i>(in thousands, except share and per share amounts)</i>		
Operating expenses:		
Research and development	\$ 15,024	\$ 12,386
General and administrative	5,747	4,848
Loss from operations	(20,771)	(17,234)
Other income, net	169	701
Net loss	\$ (20,602)	\$ (16,533)
Net loss per common share - basic and diluted	\$ (0.74)	\$ (0.60)
Weighted-average shares outstanding - basic and diluted	27,708,768	27,597,426

**Selected Balance Sheet Items:***(in thousands)*

	<b>March 31, 2022</b>	<b>December 31, 2021</b>
Cash, cash equivalents, and marketable securities	\$ 201,324	\$ 219,591
Total assets	222,746	242,386
Accounts payable and accrued expenses	6,212	6,391
Total stockholders' equity	213,936	233,386

---